An improved radiosynthesis of the muscarinic M2 radiopharmaceutical, [18F]FP-TZTP

Applied Radiation and Isotopes

Volumn 67, Issue 4, 2009, Pages 611-616

  van Oosten, Erik M ^a,b   Wilson, Alan A ^a,b   Stephenson, Karin A ^a,b   Mamo, David C ^a,b   Pollock, Bruce G ^a,b   Mulsant, Benoit H ^a,b   Yudin, Andrei K ^a   Houle, Sylvain ^a,b   Vasdev, Neil ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Fluorine 18; FP TZTP; M2; Muscarinic receptor; PET

Indexed keywords

FLUORINE-18; FP-TZTP; M2; MUSCARINIC RECEPTOR; PET;

DIAGNOSTIC RADIOGRAPHY; FLUORINE; MEDICAL IMAGING; POSITRON ANNIHILATION SPECTROSCOPY; POTASSIUM; RADIOISOTOPES; TOMOGRAPHY;

POSITRON EMISSION TOMOGRAPHY;

3 [4 (1 METHYL 1,2,5,6 TETRAHYDROPYRIDIN 3 YL) 1,2,5 THIADIAZOL 3 YLTHIO] PROPYL 4 METHYLBENZENESULFONATE; 3 [4 (3 FLUOROPROPYLTHIO) 1,2,5 THIADIAZOL 3 YL] 1 METHYL 1,2,5,6 TETRAHYDROPYRIDINE F 18; BENZENESULFONIC ACID DERIVATIVE; FLUORINE 18; MUSCARINIC M2 RECEPTOR AGONIST; NUCLEOPHILE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; FLUORINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHEMISTRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PYRIDINES; RADIOPHARMACEUTICALS; RECEPTOR, MUSCARINIC M2; THIAZOLES;

EID: 59949100116     PISSN: 09698043     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apradiso.2008.12.015     Document Type: Article

References (25)

1. Aubert I., Araujo D.M., Cecyre D., Robitaille Y., Gauthier S., and Quirion R. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J. Neurochem. 58 (1992) 529-541
2. Benson B.E., Carson R.E., Kiesewetter D.O., Herscovitch P., Eckelman W.C., Post R.M., and Ketter T.A. A potential cholinergic mechanism of Procaine's Limbic activation. Neuropsychopharmacology 29 (2004) 1239-1250
3. Cannon D.M., Carson R.E., Nugent A.C., Eckelman W.C., Kiesewetter D.O., Williams J., Rollis D., Drevets M., Gandhi S., Solorio G., and Drevets W.C. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch. Gen. Psychiatry 63 (2006) 741-747
4. 18F]FP-TZTP: control and competition studies. J. Cereb. Blood Flow Metab. 18 (1998) 1130-1142
5. 18FP-TZTP. Synapse 60 (2006) 86-92
6. Cohen R.M., Podruchny T.A., Bokde A.L.W., Carson R.E., Herscovitch P., Kiesewetter D.O., Eckelman W.C., and Sunderland T. Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-ε4 allele. Synapse 49 (2003) 150-156
7. Eckelman W.C. Radiolabeled muscarinic radioligands for in vivo studies. Nucl. Med. Biol. 28 (2001) 485-491
8. Eckelman W.C. Accelerating drug discovery and development through in vivo imaging. Nucl. Med. Biol. 29 (2002) 777-782
9. Eckelman W.C. The use of gene-manipulated mice in the validation of receptor binding radiotracer. Nucl. Med. Biol. 30 (2003) 851-860
10. Hilton J., Yokoi F., Dannals R.F., Ravert H.T., Szabo Z., and Wong D.F. Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl. Med. Biol. 27 (2000) 627-630
11. 18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology 44 (2003) 653-661
12. 18F]FP-TZTP. Nucl. Med. Biol. 30 (2003) 73-77
13. Kiesewetter D.O., Carson R.E., Jagoda E.M., Herscovitch P., and Eckelman W.C. In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazolyl tetrahydropyridines. Synapse 31 (1999) 29-40
14. 18F-labeled muscarinic agonist with M2 selectivity. J. Med. Chem. 38 (1995) 5-8
15. 18F]FDG preparations. Nucl. Med. Biol. 24 (1997) 193-195
16. Podruchny T.A., Connolly C., Bokde A., Herscovitch P., Eckelman W.C., Kiesewetter D.O., Sunderland T., Carson R.E., and Cohen R.M. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48 (2003) 39-44
17. Quirion R., Aubert I., Labchak P.A., Schaum R.P., Teolis S., Gauthier S., and Araujo D.M. Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease. Trends Pharmacol. Sci. (1989) 80-84
18. 18F]FP-TZTP bind preferentially to the M2 muscarinic receptor?. Eur. J. Nucl. Med. Mol. Imaging 33 (2006) 292-300
19. 11C-labeled TZTP for imaging muscarinic M2 receptors with PET. Nucl. Med. Biol. 35 (2008) 287-298
20. Rodríguez-Puertas R., Pascual J., Vilaró T., and Pazos A. Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 26 (1997) 341-350
21. Sauerberg P., Olesen P.H., Nielsen S., Treppendahl S., Sheardown M.J., Honore T., Mitch C.H., Ward J.S., Pike A.J., Bymaster F.P., Sawyer B.D., and Shannon H.E. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-Thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J. Med. Chem. 35 (1992) 2275-2283
22. 18F]F-PHNO. Nucl. Med. Biol. 34 (2007) 195-203
23. Waterhouse R.N. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol. Imaging Biol. 5 (2003) 376-389
24. Wilson A.A., Jin L., Garcia A., DaSilva J.N., and Houle S. An admonition when measuring the lipophilicity of radiotracers using counting techniques. Appl. Radiat. Isot. 54 (2001) 203-208
25. 11C]-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. J. Med. Chem. 48 (2005) 4153-4160